Topher Brooke is Vice President, Diabetes. In this role, he is responsible for the AstraZeneca Diabetes portfolio and the Diabetes Sales teams.
Prior to that, he served as Vice President, Infectious Disease Franchise Head inside the Specialty Care Division of MedImmune where he had responsibility for the sales and marketing teams for SYNAGIS and FLUMIST. He was also the Chair of the partnership with Abbvie for SYNAGIS internationally as well as leading the late-stage Established Product Teams. Topher also served as Vice President, Emerging Brands where he built and led a team of global strategic marketers. His team provided the commercial perspective into the pipeline development plans and provided strategic guidance on therapeutic and disease area strategies. Topher’s responsibility covered 5 therapeutic areas (RIA-respiratory, inflammation and autoimmune, oncology, infectious disease, cardiovascular/ gastroenterology, and neuroscience) and 40 assets in clinical development. Topher joined MedImmune in 2008 to start the Portfolio Management Group, where his team designed a process and methodology to assess the technical feasibility and commercial value of the pipeline assets. While in Emerging Brands, his team developed the first MedImmune corporate strategy and led the commercial diligence on over 40 business development opportunities.
Prior to joining MedImmune, Topher worked at Centocor (Johnson and Johnson). He held several positions in marketing and sales management in the Immunology Group, and led the launch of REMICADE into Ulcerative Colitis and Pediatric Crohn’s Disease. Topher also worked on the launch readiness for Simponi and Stelara.
Topher holds a BA in Philosophy from Colgate University and a MBA in Marketing and Strategy from The Wharton School, University of Pennsylvania.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.